Speaking to reporters on the sidelines of a ceremony unveiling the latest achievements of the Nuclear Science and Technology Research Institute, Eslami responded to recent remarks by IAEA Director General Rafael Grossi regarding the resumption of inspections in Iran.
Eslami said inspections had been conducted at facilities that were not attacked, but emphasized that the key issue now concerns nuclear sites that were subjected to military strikes. He stated that inspections of such facilities require a clear and defined protocol.
“The Agency, which has issued no condemnation [regarding Israel and US attacks on Iran in June] and has no established guidelines, has no right to claim it intends to conduct inspections,” Eslami said.
He added that Iran has formally collaborated with the IAEA, but no official position, condemnation, or concrete action has been taken by the Agency. “Pressure exerted on us under the influence of Israel, three European countries, and the United States has no impact on Iran. It is the Agency that must answer—to Iran and to the world,” he said.
Eslami stressed that all of Iran’s nuclear facilities are fully registered with and have been under IAEA supervision. He said the current situation demands accountability from the Agency, not further questioning of Iran, calling on the IAEA to clarify its position, explain why no condemnation was issued, and specify what procedures it intends to follow.
On June 13, 2025, Israel launched a blatant and unprovoked aggression against Iran while Washington and Tehran were in a process of nuclear negotiations. The Israeli attack triggered a 12-day war that killed at least 1,064 people in the country, including military commanders, nuclear scientists, and ordinary civilians.
The United States also entered the war by bombing three Iranian nuclear sites in a grave violation of international law.
In response, the Iranian Armed Forces targeted strategic sites across the occupied territories as well as the Al-Udeid air base in Qatar, the largest American military base in West Asia.
On June 24, Iran, through its successful retaliatory operations against both the Israeli regime and the US, managed to impose a halt to the aggression.
Elsewhere in his remarks, Eslami added that Iranian nuclear products, including radiopharmaceuticals and heavy water derivatives, are in demand across dozens of countries and continue to secure a place in global markets.
Eslami said approximately 56 countries have expressed demand for Iran’s nuclear-related products and continue to seek access to them. He noted that Iran is currently exporting to countries that are not facing transportation restrictions caused by sanctions.
Regarding countries affected by sanctions-related transport limitations, Eslami said efforts are underway to ensure Iranian products reach end users through available channels.
He emphasized that Iran’s nuclear products meet international standards and have established a position in global markets. According to Eslami, this presence is not only stable but expanding, as growing demand reflects confidence among consumers seeking to use Iranian products.
Iran on Monday morning showcased three cutting-edge achievements in nuclear science today, highlighting advancements in medical and research applications as well as the launch of the national nuclear network.
The unveiling ceremony took place on Monday morning at the Tehran International Exhibition Center, attended by Mohammad Reza Aref, Vice President of Iran, and Mohammad Eslami, head of the Atomic Energy Organization of Iran.
During the event, the Nuclear Science and Technology Research Institute introduced a diagnostic radiopharmaceutical, Gallium-68, designed for imaging metastatic melanoma, a therapeutic radiopharmaceutical, Lutetium-177, and a fully automated device for treating bone pain.
In addition to these innovations, the ceremony marked the operational launch of Iran’s National Nuclear Network, aimed at enhancing research capabilities and fostering collaboration across the country’s nuclear sector.
Speaking at the ceremony, AEOI chief Mohammad Eslami said that the Atomic Energy Organization of Iran has prioritized innovation and rapid transformation of ideas into products.
He noted that in 2023, during the same exhibition, Iran had reported the production of 50 radiopharmaceuticals, a figure that has now increased to 70, with 20 more currently in the research phase.
MNA